Gene/Protein Disease Symptom Drug Enzyme Compound
Pivot Concepts:   Target Concepts:
Query: UMLS:C0699790 (colon cancer)
 28,837 document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)

The postoperative survival rate after radical surgery for large intestinal cancer shown to be differentiated adenocarcinoma is relatively good. However, the effect of surgical adjuvant therapy on this cancer is considered to be the least promising. 5-FU, FT-207, MMC, ADR and VCR are used for chemotherapy and OK-432, PSK, BCG, levamisole and lentinan are also used as forms of immune therapy. There are no significant differences in the statistics used for comparison with controls as to the effects of these adjuvant therapies. A more intensive regional therapy has therefore been adopted for local recurrence of rectal cancer and liver metastasis of colon cancer considering the form of postoperative cancer recurrence. MMC was injected into the superior rectal artery for rectal cancer and into the portal vein during surgery for colon cancer in the 1st program of research of the Kajitani group. However, the efficacy of these procedures was not proved. Although immune therapy with OK-432 has also been subsequently added in the second research program, no efficacy was apparent. Taylor and Birmingham have reported that liver metastasis was remarkably decreased by continuous infusion of 5-FU through the portal vein. There is also a report by GITSG in the USA that a reduction of local recurrence was obtained by combination of 5-FU and Me-CCNU with irradiation treatment after surgery for rectal cancer.
 ...
PMID:[Surgery and adjuvant therapy of cancer of the large intestine]. 308 76

The results obtained with a three-fold association of drugs (VCR, 5Fu, MeCCNU) in the treatment of 68 patients suffering from advanced carcinoma of the gastroenteric system followed up over an approximately four year period at the Savona Oncology Centre are reported. The percentage of positive responses (CR + PR) was 75% for carcinoma of the colon-rectum and 44.4% for stomach cancer. The results obtained in intestinal carcinoma proved more satisfactory than those reported in the literature. This could be attributed to the contemporaneous use of Corynebacterium parvum which boosts the immunitary state and so enhances the defences of the host organism, making it more sensitive to polychemotherapy. In the light of this hypothesis, stress is laid on the need to use an immunochemotherapy approach for the treatment of advanced carcinoma of the gastroenteric apparatus.
 ...
PMID:[Immunochemotherapeutic treatment of gastrointestinal neoplasms]. 730 Nov 83

A novel series of 2-substituted aminomethyl-9-alkyl-1,2,3,4-tetrahydrocarbazole-1-ones 5a-q was synthesized via aminomethylation of 9-alkyl-1,2,3,4-tetrahydrocarbazole-1-ones 4a-e with hydrochlorides of the respective amines 6a-m. The structures of these newly synthesized compounds were characterized by (1)H-NMR, MS, and elemental analysis. All the compounds were tested for their cytotoxic activity in vitro against four human tumor cell lines including human non-small lung cancer cells (A549), human gastric adenocarcinoma (SGC), human colon cancer cell (HCT116), human myeoloid leukemia cells (K562), and one multi-drug resistant subline (KB-VCR). Most compounds showed moderate to potent cytotoxic activity against the tested cell lines. Preliminary mechanism research indicated that the most promising compound, 2-diethylaminomethyl-9-methyl-1,2,3,4-tetrahydrocarbazole-1-one 5c, exhibited a potential inhibitory effect against microtubule.
 ...
PMID:Synthesis and in-vitro antitumor activities of some mannich bases of 9-alkyl-1,2,3,4-tetrahydrocarbazole-1-ones. 1921 85

Previous studies have reported that 8-c [6-(2-(2-(dimethylamino)ethylamino)ethylamino)-2-octyl-1H-benzo[de]isoquinoline-1,3(2H)-dione], a novel amonafide analogue, was generated as a new anticancer candidate. However, little is known about its activity in chemoresistant cells. In this study, the antitumor effects of 8-c on the multi-drug-resistant human colorectal carcinoma cancer cell lines HCT-116/L-OHP and HCT-8/VCR have been investigated for the first time. 8-c showed similar concentration-dependent inhibitory activities against multi-drug-resistant cells and corresponding parental cell lines by the MTT assay after 48 h of treatment. 8-c treatment resulted in the induction of apoptosis, as evidenced by fluorescent staining analysis, comet assay data, and the increase in the number of apoptotic cells as detected by flow cytometry. Western blot, qPCR, and siRNA techniques were used to elucidate the molecular mechanism. Our study suggested that the apoptotic effect of 8-c can be attributed to the upregulation of p53, caspase-3, and cleaved poly(ADP-ribose) polymerase (PARP) and the downregulation of Bcl-2. Furthermore, ERCC1 is essential for nucleotide excision repair. ERCC1 expression was correlated with sensitivity to chemotherapy in various colon cancer cell lines. It is intriguing that decreases in ERCC1 protein and mRNA levels were also observed in the HCT-116/L-OHP and HCT-8/VCR cells after exposure to 8-c. Further transient transfection of multi-drug-resistant cells with ERCC1 siRNA enhanced 8-c-induced cytotoxicity. In contrast, epidermal growth factor-induced increase in ERCC1 protein levels was shown to rescue cell viability upon 8-c treatment. These findings suggest that 8-c has a strong potential to be developed as a new antitumor agent for the treatment of multi-drug-resistant colon cancer cells, and is worthy of further studies.
 ...
PMID:Induction of apoptosis and suppression of ERCC1 expression by the potent amonafide analogue 8-c in human colorectal carcinoma cells. 2342 74